Findings

What do systematic reviews say?

3 questions · 3 findings · 2 reviews · Musculoskeletal

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 2 · 66.7%Low 0 · 0%Moderate 1 · 33.3%High 0 · 0%

Rituximab (2 x 1000 mg) plus methotrexate vs methotrexate

Clinical remission · patients with rheumatoid arthritis

Rituximab (2 x 1000 mg) plus methotrexate showed no clear difference in clinical remission (Disease Activity Score‐28 joint count < 2.6)… compared with methotrexate monotherapy (moderate certainty).

1 finding from 1 review

Rituximab for rheumatoid arthritis 2015 · Cochrane Headline outcomes only
RR 9.1 [0.76, 108.2]
2 studies · 834 participants
Moderate

Infliximab vs rituximab

Remission · adults (age 18 years and older) with refractory GPA ANCA‐associated vasculitis

It is very uncertain whether infliximab changes remission compared with rituximab (very low certainty).

1 finding from 1 review

Anti‐cytokine targeted therapies for ANCA‐associated vasculitis 2020 · Cochrane Headline outcomes only
RR 0.44 [0.11, 1.81]
Studies not reported
Very low

Infliximab vs rituximab

Durable remission during additional · adults (age 18 years and older) with refractory GPA ANCA‐associated vasculitis

It is very uncertain whether infliximab changes durable remission during additional compared with rituximab (very low certainty).

1 finding from 1 review

Anti‐cytokine targeted therapies for ANCA‐associated vasculitis 2020 · Cochrane Headline outcomes only
RR 0.22 [0.03, 1.6]
Studies not reported
Very low